🇺🇸 FDA
Pipeline program

VLY-686 (Tradipitant)

VP-VLY-686-2301

Phase 2 small_molecule completed

Quick answer

VLY-686 (Tradipitant) for Gastroparesis is a Phase 2 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Gastroparesis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials